GlassScriptPhysician profile
Sarah M Carter
NPI 1750549168
$1,593.51
in general payments reported to CMS, 2019-2025
33 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $96.82 · 2021: $71.00 · 2022: $88.76 · 2023: $354 · 2024: $308 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,048.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $215.80 | 2022-2025 | |
| Novo Nordisk INC | $167.57 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Boston Scientific Corporation | $158.29 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Amgen INC. | $108.15 | 2019-2025 | Krystexxa, Evenity |
| Abbvie INC. | $97.39 | 2021-2025 | Ubrelvy, Dalvance, Qulipta |
| Lilly USA, LLC | $90.85 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $82.95 | 2020-2025 | Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $62.94 | 2025 | Inspire |
| Eisai INC. | $50.05 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $39.65 | 2023-2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $38.16 | 2019-2024 | |
| Baxter Healthcare | $37.32 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Amarin Pharma, INC. | $36.03 | 2020 | |
| Daiichi Sankyo INC. | $34.41 | 2020-2021 | |
| Medtronic, INC. | $32.27 | 2024-2025 | Intellis Adaptivestim |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.00 | 2025 | Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $27.07 | 2019 | |
| Biosense Webster, INC. | $27.04 | 2019 | |
| Abbott Laboratories | $24.67 | 2024 | Freestyle Libre 3 |
| Lundbeck LLC | $23.96 | 2024 | Vyepti |
| Gilead Sciences, INC. | $19.47 | 2023 | |
| Novartis Pharmaceuticals Corporation | $18.29 | 2022 | |
| Axsome Therapeutics, INC. | $18.11 | 2023 | Auvelity |
| Scilex Pharmaceuticals INC. | $17.81 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.74 | 2023 | Gvoke Hypopen |
| Currax Pharmaceuticals LLC | $17.30 | 2024 | Contrave |
| Tris Pharma INC | $16.24 | 2024 | Dyanavel Xr |
| Edwards Lifesciences Corporation | $15.91 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Welch Allyn | $15.62 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.17 | 2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $12.73 | 2021 | |
| Ibsa Pharma INC. | $11.84 | 2022 | |
| Seqirus USA INC | $11.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.